Literature DB >> 17296554

Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.

Masafumi Ihara1, Nobuyuki Yamasaki, Akari Hagiwara, Ai Tanigaki, Ayumi Kitano, Rie Hikawa, Hidekazu Tomimoto, Makoto Noda, Masashi Takanashi, Hideo Mori, Nobutaka Hattori, Tsuyoshi Miyakawa, Makoto Kinoshita.   

Abstract

In Parkinson disease (PD), alpha-synuclein aggregates called Lewy bodies often involve and sequester Septin4 (Sept4), a polymerizing scaffold protein. However, the pathophysiological significance of this phenomenon is unclear. Here, we show the physiological association of Sept4 with alpha-synuclein, the dopamine transporter, and other presynaptic proteins in dopaminergic neurons; mice lacking Sept4 exhibit diminished dopaminergic neurotransmission due to scarcity of these presynaptic proteins. These data demonstrate an important role for septin scaffolds in the brain. In transgenic mice that express human alpha-synuclein(A53T) (a mutant protein responsible for familial PD), loss of Sept4 significantly enhances neuropathology and locomotor deterioration. In this PD model, insoluble deposits of Ser129-phosphorylated alpha-synuclein(A53T) are negatively correlated with the dosage of Sept4. In vitro, direct association with Sept4 protects alpha-synuclein against self-aggregation and Ser129 phosphorylation. Taken together, these data show that Sept4 may be involved in PD as a dual susceptibility factor, as its insufficiency can diminish dopaminergic neurotransmission and enhance alpha-synuclein neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296554     DOI: 10.1016/j.neuron.2007.01.019

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  69 in total

Review 1.  Application of in utero electroporation and live imaging in the analyses of neuronal migration during mouse brain development.

Authors:  Yoshiaki V Nishimura; Tomoyasu Shinoda; Yutaka Inaguma; Hidenori Ito; Koh-Ichi Nagata
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

Review 2.  The emerging functions of septins in metazoans.

Authors:  Juha Saarikangas; Yves Barral
Journal:  EMBO Rep       Date:  2011-10-28       Impact factor: 8.807

Review 3.  The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration.

Authors:  Ai Yamamoto; Anne Simonsen
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

4.  Septin 8 is an interaction partner and in vitro substrate of MK5.

Authors:  Alexey Shiryaev; Sergiy Kostenko; Gianina Dumitriu; Ugo Moens
Journal:  World J Biol Chem       Date:  2012-05-26

5.  Seeking truth on Monte Verita. Workshop on the molecular biology and biochemistry of septins and septin function.

Authors:  Amy S Gladfelter; Cristina Montagna
Journal:  EMBO Rep       Date:  2007-11-02       Impact factor: 8.807

Review 6.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

7.  Regulation of distinct septin rings in a single cell by Elm1p and Gin4p kinases.

Authors:  Bradley S DeMay; Rebecca A Meseroll; Patricia Occhipinti; Amy S Gladfelter
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

8.  Role of nucleotide binding in septin-septin interactions and septin localization in Saccharomyces cerevisiae.

Authors:  Satish Nagaraj; Ashok Rajendran; Charles E Jackson; Mark S Longtine
Journal:  Mol Cell Biol       Date:  2008-06-09       Impact factor: 4.272

Review 9.  Value of genetic models in understanding the cause and mechanisms of Parkinson's disease.

Authors:  Darren J Moore; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 10.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.